Related Experiment Video
Updated: Jul 1, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
Published on: July 17, 2020
Thymidine phoshorylase as a target for antiangiogenesis treatment
G J Peters1, I V Bijnsdorp, M Fukushima
1Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands. gj.peters@vumc.nl
Abstract:
Thymidine phosphorylase (TP) has emerged as a promising target for antiangiogenesis treatment of cancer. Angiogenesis, the formation of blood vessels, is essential for tumors to grow in order to be supplied with nutrients and oxygen. The association of TP with angiogenesis was demonstrated in several clinical studies in various tissue types. It has been postulated that the angiogenic effect of TP is related to its enzymatic activity, which catalyzes the breakdown of thymidine to thymine and deoxyribose-1-phosphate (dR-1-P). The latter, in its parent form or in its sugar form, deoxyribose, may play a role in angiogenesis. It may interfere in cellular energy metabolism or be substrate in a chemical reaction generating reactive oxygen species. L-deoxyribose and a specific TP inhibitor, TPI, can reverse these effects, supporting the role of the enzymatic reaction and that of the sugar. Although TP is usually high in the tumor, we also observed a high expression in tumor-associated stromal cells and macrophages. In order to elucidate the mechanism of TP induced angiogenesis we have investigated the association of TP with angiogenesis, the effect of thymidine and its metabolites on angiogenic parameters (e.g. invasion), the modulation by TPI, the formation and retention of the sugar metabolites of thymidine, and the potential signalling pathways involved in the angiogenic process. We used cell lines without/low TP expression (Colo320 and RT112) and TP transfected variants (Colo320TP1 and RT112/TP). Intrinsic TP expression in cancer cells did not stimulate these cells to invade more. On the other hand, Colo320 and Colo320TP1 cells could attract endothelial cells to a high extent, but Colo320TP1 did not attract them to a higher extent. RT112/TP cells attracted more endothelial cells than RT112 (2 fold). The difference between the RT112's and Colo320's may be related to different formation of sugars. Exposure of tumor cells to thymidine resulted in a rapid formation of dR-1-P, which was rapidly degraded to deoxyribose and further metabolized to other sugar derivatives. Of the possible sugars that can be produced by the conversion of TdR, dR-5-P seems to accumulate the most. dR accumulated 3 fold higher extent in RT112/TP than in Colo320/TP1 cells. dR could be converted to advanced glycation endproducts (AGE), however this was to a lower extent than ribose. Thymidine also induced several signalling pathways in the cells, involved in migration and invasion, such as the Focal adhesion kinase (FAK), which subsequently stimulated p70/S6 phosphorylation. The latter is a downstream kinase of rapamycin and its phosphorylation is inhibited by rapamycin, an mTOR inhibitor. The association between rapamycin and TP was shown by the protection by thymidine of rapamycin induced cytotoxicity, while TPI inhibited the effect of thymidine addition. These studies clearly show a mechanistic link between TP, signalling pathways, and cell migration.
Insights
Thymidine phosphorylase (TP) drives cancer angiogenesis by breaking down thymidine into sugars that promote cell migration and invasion. Inhibiting TP or its sugar metabolites can block these pro-angiogenic effects.
Area of Science:
- Biochemistry
- Cancer Biology
- Molecular Oncology
Background:
- Thymidine phosphorylase (TP) is a key enzyme implicated in cancer angiogenesis, the process of new blood vessel formation essential for tumor growth.
- TP catalyzes thymidine breakdown, producing metabolites like deoxyribose-1-phosphate (dR-1-P) and deoxyribose (dR), which may contribute to angiogenesis.
- TP is often overexpressed in tumors and associated stromal cells, suggesting a significant role in the tumor microenvironment.
Purpose of the Study:
- To elucidate the mechanistic link between TP, its enzymatic activity, thymidine metabolites, and cancer angiogenesis.
- To investigate the role of TP-generated sugars in promoting endothelial cell attraction, invasion, and specific signaling pathways.
- To evaluate the therapeutic potential of TP inhibition (TPI) in modulating these angiogenic processes.
Main Methods:
- Utilized cancer cell lines with varying TP expression levels (wild-type and TP-transfected variants).
- Assessed endothelial cell attraction, invasion, and metabolite formation (dR-1-P, dR, dR-5-P) following thymidine exposure.
- Investigated TP's impact on signaling pathways (e.g., FAK, p70/S6) and its interaction with mTOR inhibitors (rapamycin).
Main Results:
- TP expression in cancer cells enhanced endothelial cell attraction, particularly in RT112/TP cells, linked to differential sugar metabolite formation.
- Thymidine exposure led to rapid dR-1-P formation, subsequent degradation to dR, and accumulation of dR-5-P, with higher levels in RT112/TP cells.
- TP activation of FAK and p70/S6 signaling pathways was observed, promoting cell migration, and thymidine protected against rapamycin-induced cytotoxicity, an effect reversed by TPI.
Conclusions:
- TP plays a critical role in promoting cancer angiogenesis and cell migration through its enzymatic activity and the generation of specific sugar metabolites.
- The study establishes a mechanistic link between TP, thymidine metabolism, key signaling pathways (FAK, mTOR/p70S6K), and enhanced cell migration.
- Targeting TP and its downstream metabolic and signaling pathways represents a promising strategy for anti-angiogenesis cancer therapy.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Inhibition of Cdk Activity
Regulation of Angiogenesis and Blood Supply
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase